Loading...
Market
GSK mRNA COVID-19 vaccine FDA approval by end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
GSK Acquires Full Rights to Develop mRNA Flu and COVID-19 Vaccines from CureVac for €1.4 Billion
Jul 3, 2024, 07:27 AM
GSK and CureVac have restructured their collaboration into a new licensing agreement. As part of the deal, GSK will acquire full rights to develop and manufacture mRNA flu and COVID-19 shots from CureVac. The agreement includes a payment of up to €1.4 billion.
View original story
Similar markets
Positive • 33%
Neutral • 33%
Negative • 33%
USA • 25%
EU • 25%
UK • 25%
Other • 25%
Full recall • 25%
Partial recall • 25%
No recall but warning issued • 25%
No action • 25%